Romo1 is associated with ROS production and cellular growth in human gliomas
| Autor: | Yang Seok Chae, Yong Gu Chung, Se-Hyuk Kim, Kyung Jae Park, Dong Hyuk Park, Mi Ok Yu, Sung Gil Chi, Shin Hyuk Kang, Na Hyun Song |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Cancer Research
Pathology medicine.medical_specialty Carcinogenesis Biology Mitochondrial Proteins Pathogenesis Mice Downregulation and upregulation Cell Line Tumor Glioma medicine Animals Humans RNA Messenger Cell Proliferation Gene knockdown Brain Neoplasms Cell growth Cell Cycle Brain Membrane Proteins Cell cycle medicine.disease In vitro Neurology Oncology Cell culture Gene Knockdown Techniques Cancer research Neurology (clinical) Neoplasm Grading Reactive Oxygen Species Neoplasm Transplantation |
| Zdroj: | Journal of Neuro-Oncology. 121:73-81 |
| ISSN: | 1573-7373 0167-594X |
| DOI: | 10.1007/s11060-014-1608-x |
| Popis: | Romo1 is a mitochondrial protein whose elevated expression is commonly observed in various types of human cancers. However, the expression status of Romo1 and its implication in the pathogenesis of human glioblastoma (GBM) remain largely undefined. To understand the role of Romo1 in the progression of GBM, we explored its expression in a series of GBM tissues and cell lines and determined its effect on ROS production, cell proliferation, and tumor growth. Romo1 was frequently overexpressed at the mRNA level in both primary tumors and cell lines and its elevation was more commonly observed in high grade tumors versus low grade tumors. Romo1 expression was associated with ROS production and its knockdown led to a marked reduction of in vitro cellular growth and anchorage-independent growth of GBM. Consistently, Romo1 depletion induced a G2/M arrest of the cell cycle that was accompanied with accumulation of phospho-cdc2. Furthermore, a mouse xenograft assay revealed that Romo1 depletion significantly decreased tumor formation and growth. Therefore, our data demonstrate that Romo1 upregulation is a common event in human GBMs and contributes to the malignant tumor progression, suggesting that Romo1 could be a new therapeutic target for human GBM. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink